Despite advances in the curative treatment of acute myeloid leukemia (AML), recurrence will occur in the majority of cases. At diagnosis, acquisition of segmental uniparental disomy (UPD) by mitotic recombination has been reported in 15-20% of AML cases, associated with homozygous mutations in the region of loss of heterozygosity. This study aimed to discover if clonal evolution from heterozygous to homozygous mutations by mitotic recombination provides a mechanism for relapse. DNA from 27 paired diagnostic and relapsed AML samples were analyzed using genotyping arrays. Newly acquired segmental UPDs were observed at relapse in 11 AML samples (40%). Six were segmental UPDs of chromosome 13q, which were demonstrated to lead to a change from heterozygosity to homozygosity for internal tandem duplication mutation of FLT3 (FLT3
Introduction
Dramatic advances have been made over the last 40 years in the treatment of acute myeloid leukemia (AML) such that 40-50% of patients presenting under the age of 60 years can be cured with initial therapy. [1] [2] [3] Complete remission, determined clinically, morphologically, immunologically and sometimes at the molecular level is reliably reported to be achieved in up to 80% of patients in this age group. 3 Despite this success, reemergence of leukemia is the rule rather than the exception; at least 50% of younger patients and 80% of those over 60 years will see their leukemia return within 5 years. 4, 5 Data from our institution similarly demonstrates that two-thirds who achieve first complete remission, subsequently relapse. Although a second remission may be achieved, it is rarely sustained, even when allogeneic stem cell transplantation is successful, such that only 20% of adult patients survive at 4 years. 6 Hence, there is a compelling urgency to determine mechanisms of resistance in order to identify appropriate alternative treatment strategies.
Cytogenetic abnormalities are the most important biological prognostic factors for risk of relapse, with the occurrence of rearrangements involving inv (16) , t(8;21) and t (15;17) associated with a better prognosis, and AML patients with deletions involving chromosomes 7q, 5q and abnormalities of 3q amongst those having the poorest prognosis. 4 Three case series have reviewed cytogenetic changes at diagnosis and relapse. [7] [8] [9] No consistent cytogenetic abnormalities were acquired at relapse; therefore, it
is not clear what role acquired karyotypic abnormalities play in the pathogenesis of relapse.
Resistance to chemotherapy is intrinsic to relapsed leukemic cells. The presence of a chemoresistant population of leukemic cells is demonstrated by the detection of minimal residual disease after chemotherapy, which increases the risk of relapse for some
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Single gene mutations are an additional biological risk factor for relapse, with FLT3 internal tandem duplication (ITD) being an important predictor of poor prognosis. 13 Where FLT3 ITD is detected at diagnosis, the same mutation is noted at relapse in 75% of cases. 14 Some of these have been found to have an increased dosage of mutant FLT3 at disease recurrence, suggesting a clonal out growth of a cell with a homozygous or hemizygous mutation. 14 Homozygous single gene mutations are known to occur in AML and these are associated with mitotic recombination or possibly a non-disjunction event leading to acquired uniparental disomy (UPD) also known as acquired isodisomy. 15 Studies of acquired UPD in diagnostic AML samples give a frequency of 15-20%, 16, 17 with the largest study to date having analyzed 454 samples. 18 A possible mechanism for relapse in AML is one in which a heterozygous mutation is followed by a recombination event leading to homozygosity and clonal evolution. To evaluate this hypothesis, 27 paired diagnosis and relapse AML samples were studied using array-based genome-wide mapping to identify regions of segmental UPD and gene specific mutation analysis.
Materials and Methods

Sample Selection
Sufficient paired diagnostic and relapse blood and bone marrow samples for analysis were available from 27 patients with AML. 
10K GeneChip Assay
DNA was extracted using standard phenol-chloroform techniques, or from the organic phase of TRIzol (Invitrogen, Carlsbad, CA). The GeneChip mapping assay protocol (Affymetrix Inc., Santa Clara) was used to produce the 10K SNP array results and is described elsewhere. 20, 21 The protocol was adapted such that the purification of polymerase chain reaction (PCR) product was performed using the Ultrafree-MC 30,000
NMWL filtration column (Millipore, Billerica, MA). Signal intensity data was analyzed by the GeneChip DNA analysis software (GDAS), which uses a model algorithm, modified partitioning around medoids (MPAM), to generate SNP calls. 22, 23 In brief, the relative allele signal (RAS) from each allele on the forward and reverse strands (RAS1 and RAS2 respectively) is used to determine heterozygosity or homozygosity (the call) for individual
SNPs. The call is made based on whether the plotted RAS values lie within the boundary of zones previously determined from a training set of human samples. 22 
Mutation analysis
Mutation screening was performed for the entire coding region of CEBPA 26, 27 and specific exons of FLT3 (exons 14-15 and 20) 28,29 using standard primer and amplification conditions. PCR products were sequenced directly by use of an ABI 377 DNA sequencer (PE Applied Biosystems, Foster City, CA). Sequencing data were analyzed using 4Peaks software (Mekentosj.com, http://mekentosj.com/4peaks). Fragment analysis of FLT3 exon 14-15 PCR products was performed using the QIAGEN Multiplex PCR kit, and measured by capillary electrophoresis using an ABI Prism 3700 Genetic Analyzer (PE Applied Biosystems, CA). Fluorescence signals were analyzed using Genotyper 3.7 software (PE Applied Biosystems, CA).
Results
Matched paired samples were analyzed by SNP array and mutation analysis at presentation and at relapse for evidence of clonal evolution. Eighteen patients acquired copy number changes at relapse and these correlated with karyotype data where available (Table 2 ). There were no consistently acquired karyotypic or copy number abnormalities at
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Three patients (patients 7,8 and 12) had acquired UPD at diagnosis. Patient 8 had UPD 13q with a homozygous FLT3 ITD mutation at diagnosis, and this was retained at relapse.
Clonal evolution of acquired UPD at relapse
Newly acquired segmental UPD at disease recurrence was detected in 11 of 27 patients (41%). The most common abnormality detected was segmental UPD of chromosome 13 which was observed in 6 of 27 patients (22%) ( Table 2 ). The smallest size of UPD was about 88Mb, including the telomere, and the largest involved the whole chromosome (114Mb). As expected for UPD, copy number analysis and karyotype analysis revealed two copies of chromosome 13 across the regions of LOH, excluding the possibility of a hemizygous deletion. All regions of UPD on 13 included the locus for FLT3.
Sequencing of FLT3 showed an ITD mutation, which was heterozygous at diagnosis and homozygous at relapse in all 6 cases (Table 3 and Figure 1 ). The mutations were identical at diagnosis and relapse in each case, demonstrating that the second clone had evolved from the initial leukemia. Three of the 6 AML patients with homozygous FLT3 ITD mutations had Patient 16 acquired segmental UPD of 19q at relapse, and this was associated with a mutation of CEBPA located within the region of homozygosity. This mutation was also heterozygous at diagnosis and homozygous at relapse. The mutation, 207 C→T (Genbank accession Y11525), created a stop codon which results in an N-terminal truncated protein. 27 A further segmental UPD was acquired at 4q in patient 21. In the absence of an obvious candidate gene and in view of the large region involved (104Mb) this was not investigated further. 
Subclones with acquired UPD
Three of the 11 patients (1, 7 and 14) acquired UPD of chromosome 13 in subclones of the relapsed leukemic cell population. Figure 2A illustrates the shift in RAS values in patient 9, where the whole leukemic population acquires UPD of chromosome 13q, as compared to patient 1 where only a subclone with UPD 13q is present. The allele call rates for all other chromosomes in the each sample were greater than 90%, indicating that changes in RAS values were not due to a failure of hybridization and the changes were not due to normal germline contamination because all samples contained >70% blasts. 30 PCR fragment analysis for FLT3 was performed on both patient 1 and 9, which was within the region of UPD ( Figure 2B ). Both patients had a reduction in wild type to mutant FLT3 ratio at relapse, consistent with the presence of a homozygous FLT3 ITD mutation.
Together with the array data, this is consistent with a leukemic cell subpopulation with UPD 13q and a homozygous FLT3 ITD mutation at disease recurrence in patient 1.
Patient 7 had a FLT3 loop mutation (D835Y), which became homozygous at relapse. Patient 14 had a heterozygous D835Y mutation at diagnosis but this was absent at relapse.
Discussion
This study demonstrates that remarkably, about 40% of AML patients exhibit newly acquired UPD at relapse. Acquired segmental UPD frequently results in a homozygous mutation, most commonly involving chromosome 13 with FLT3 ITD. Interestingly, previous studies on diagnostic material have shown that loss of wild type FLT3 in the presence of FLT3 ITD is a poor prognostic marker at presentation, 31, 32 and that a higher level of FLT3
ITD on PCR fragment analysis of genomic DNA increases the risk of relapse. 33 Acquisition of UPD of chromosome 13 provides an explanation for the increase in gene dosage at Tyrosine kinase inhibitors are currently undergoing trials in FLT3 ITD positive AML.
38,39
Following acquisition of UPD of chromosome 13, these AML cells may be even more dependent on FLT3 signaling, which suggests inhibition of FLT3 may be an effective method of treating relapse in AML patients with UPD 13q.
Biallelic mutations of CEBPA are well recognized in AML. They are occasionally homozygous 40 and these have been associated with acquired UPD of 19q. 41 Although a biallelic mutation is not a prerequisite for AML, it is important in its development, as demonstrated in familial cases of AML in which a germ line CEBPA mutation is followed after a long latency by a second CEBPA mutation and subsequently develops AML. 42 AML patients with mutations of CEBPA have a relatively good prognosis 43 . Although in this study, evolution of a homozygous CEBPA mutation was associated with relapsed AML, the numbers of AML patients with homozygous CEBPA mutations are too few to ascertain whether they would have a poorer prognosis.
Mitotic recombination or non-disjunction leads to segmental or whole chromosomal UPD respectively. It is unknown whether these events occur before, during or after treatment. A rare chemoresistant subclone with UPD may be present in the initial population at diagnosis. In vitro studies on mouse fibroblasts and normal human
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As expected, SNP arrays identified more abnormalities than cytogenetic analysis alone.
However, some cytogenetic abnormalities were not detected by SNP array, for example patient 24 acquired a rare clone with a deletion of 12p at relapse, patient 15 acquired trisomy 8 and patient 13 had a deletion of 7q. We hypothesize that in these cases, the dominant leukemic clone had a normal karyotype, but did not grow on short-term culture for karyotypic analysis.
Although the Affymetrix 10K arrays used in this study have been superceded by those at a much higher resolution, the study was designed to identify large regions of UPD due to mitotic recombination, for which the 10K arrays are quite adequate. However, higher resolution arrays have the potential to identify much smaller recombinations of only a few thousand base pairs. Additionally, with the small number of patients in this study, no significant correlations with clinical outcomes were possible. Recurrent AML defines itself as a poor prognostic group, and only five patients achieved a second remission, of which there is only one long-term survivor. The samples were selected retrospectively, based upon the availability of both a diagnostic and a relapse leukaemia sample. As a result, it was unavoidable that some subgroups were missed or under represented, e.g. acute promyelocytic leukaemias and complex karyotypes. Future studies are aimed to use higher resolution arrays in a larger sample set to discover if acquired UPD is of prognostic importance at relapse. The frequency of acquired segmental UPD at diagnosis is 15-20% [16] [17] [18] and this study appears to demonstrate an increased frequency of UPD (41%) at relapse. In particular, the incidence of 13q UPD is only 6% at diagnosis. 18 It is possible that mitotic recombination could occur more often after exposure to cytotoxic chemotherapy, perhaps due to an increased rate of DNA double strand breaks.
This study provides the first data that mitotic recombination is an important mechanism responsible for recurrence of AML. Previously, two case reports of relapsed childhood AML have described a similar phenomenon, one involving FLT3 ITD, 45 and another where a homozygous WT1 mutation was acquired at relapse. 46 In addition, several other cancers have been demonstrated to acquire UPD at diagnosis, 47,48 suggesting mitotic recombination could be a general mechanism for cancer progression. Although UPD of 13q is the commonest abnormality described here, further studies into acquired segmental
UPDs are likely to reveal novel targets in the treatment of AML and other cancers. For 
